Minerals Technologies Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with the three months ended April 2, 2023. MTI is a global specialty minerals company operating through Consumer & Specialties and Engineered Solutions. Financial statements are unaudited; KPMG’s interim review found no material modifications needed for GAAP conformity.
Financial performance
| Metric | Q1 2024 | Prior year | Change |
|---|---|---|---|
| Net sales | $534.5 million | $546.1 million | −2% |
| Production margin | $135.9 million; 25.4% | $120.7 million; 22.1% | +13% in dollars |
| Operating income | $75.2 million; 14.1% margin | $63.0 million; 11.5% margin | +19% |
| Net income attributable to MTI | $46.7 million | $37.0 million | +26% |
| Diluted EPS | $1.44 | $1.14 | +26% |
| Cash from operations | $55.9 million | $33.7 million | +$22.2 million |
Cost of goods sold declined 6%, faster than sales, and management attributed the improved production margin to pricing, cost management and productivity. Interest expense rose to $14.9 million from $14.2 million, reflecting higher rates. The effective tax rate increased to 23.1% from 22.0%, primarily due to earnings mix. Other comprehensive loss was $22.7 million, mainly from foreign-currency translation.
Segments and material comparisons
- Consumer & Specialties: Sales were $296.9 million, essentially flat. Household & Personal Care rose 7% to $138.4 million, supported by pet litter and other consumer products; Specialty Additives fell 6% to $158.5 million. Segment operating income increased 30% to $42.0 million, with a 14.1% margin versus 10.8%.
- Engineered Solutions: Sales declined 5% to $237.6 million. High-Temperature Technologies fell 1% to $177.3 million; Environmental & Infrastructure fell 14% to $60.3 million, reflecting weak North American commercial construction and completion of two large remediation projects in the prior-year quarter. Segment operating income rose 9% to $38.5 million, with a 16.2% margin versus 14.2%.
- Prior-year sales included $13.1 million from BMI, which was deconsolidated following its October 2023 Chapter 11 filing. U.S. sales decreased 4%; international sales increased 1%.
Cash, debt and liquidity
Cash and cash equivalents were $315.7 million and short-term investments were $4.4 million at quarter-end, totaling $320.1 million. Management reported more than $500 million of available liquidity, including cash and revolving-credit availability. Operating cash flow was $55.9 million; capital expenditures were $16.5 million. Investing cash use was $16.6 million and financing cash use was $32.0 million, including $15.0 million of treasury-share purchases and $3.2 million of dividends. Cash ended the quarter at $315.7 million, down $1.5 million from year-end.
Total reported borrowings were approximately $1.00 billion, comprising $75.7 million short-term debt, $21.4 million current maturities and $904.4 million long-term debt. Cash and short-term investments less these borrowings imply net debt of approximately $681 million. The $300 million revolving facility had $75.0 million drawn and $9.1 million in letters of credit outstanding. MTI reported compliance with debt covenants. The largest scheduled maturities are $443.7 million in 2027 and $400.0 million in 2028.
Outlook, risks and unusual items
- No specific full-year revenue, profit or EPS guidance is provided. MTI expects 2024 capital expenditures of $90–$100 million and describes growth priorities including product innovation, market penetration, operational excellence and selective acquisitions; execution is not assured.
- MTI recorded $2.1 million of litigation expense related to the Barretts bankruptcy. BMI had 594 open talc-related cases at March 31, all stayed as described in the filing. BMI agreed to sell its talc assets under Bankruptcy Code section 363, with closing expected in Q2 2024; proceeds are intended to fund the Chapter 11 cases. The ultimate resolution, timing and potential losses remain uncertain, and MTI cannot estimate a loss range. Pfizer indemnification arrangements may cover some liabilities.
- Other disclosed risks include economic and end-market cyclicality, competition, raw-material, energy and shipping costs, foreign-exchange and interest-rate exposure, production and capacity constraints, regulation, cybersecurity and debt service/covenant compliance. A one-percentage-point interest-rate change would affect annual interest expense by an estimated $3.8 million, inclusive of derivatives.
- The board’s $75 million repurchase authorization had 443,775 shares repurchased for $29.2 million through March 31, 2024. The quarterly dividend declared was $0.10 per share, versus $0.05 a year earlier.
Important facts for investors to verify
- Whether margin improvement and stronger segment operating income persist despite lower consolidated sales and weaker Engineered Solutions demand.
- Progress and outcomes of BMI’s asset sale and Chapter 11 process, including any implications for non-debtor affiliates, indemnification and future talc-related costs.
- Debt maturities, borrowing costs, available revolver capacity and continued covenant compliance.
- Delivery against the $90–$100 million capital-spending outlook and the expected returns from growth initiatives and share repurchases.
- Foreign-exchange effects and the sensitivity of interest costs to rates; quarter-end foreign-currency translation reduced comprehensive income.